Single-cell and Bulk Transcriptomic Profiling of Anti-PCSK9-Armed Oncolytic Virus Therapy Reveals MHC-I Rewiring and Durable CD8 T Cell Immunity in Colorectal Cancer
Sequencing datasets were generated using single-cell transcriptomic profiling and bulk transcriptomic sequencing (bulk RNA-seq) to characterize tumor and immune responses to oncolytic virus (OV) therapy in colorectal cancer models. Tumors treated with oncolytic VSVDelta51, PCSK9 inhibition, the combination regimen, and matched controls were collected to evaluate OV-driven alterations in antigen presentation and T cell signaling within the tumor microenvironment at single-cell resolution, while bulk RNA-seq provided complementary tissue-level transcriptional changes and support for key pathway and antigen-presentation programs. The study investigates OV-induced PCSK9 upregulation and MHC-I modulation across malignant and bystander cell populations, and quantifies associated shifts in tumor-infiltrating T cell states, clonal and functional programs, and features of immune memory inferred from single-cell profiles, with bulk analyses corroborating treatment-associated remodeling of antigen-processing and immune activation signatures at the tissue level.